Evidence map›Paper›PMID 27704149›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2017

Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.

C Baues, R Semrau, U S Gaipl, P J Bröckelmann, J Rosenbrock, A Engert, S Marnitz

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Harnessing Immune Response in Acute Myeloid Leukemia.Journal of clinical medicine · 2023
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

C BauesMedical Faculty, Department of Radiooncology, University of Cologne, Cologne, Germany. christian.baues@uk-koeln.de.
R SemrauMedical Faculty, Department of Radiooncology, University of Cologne, Cologne, Germany.
U S GaiplDepartment of Radiooncology, University hospital Erlangen, Erlangen, Germany.
P J BröckelmannGerman Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany.
J RosenbrockMedical Faculty, Department of Radiooncology, University of Cologne, Cologne, Germany.
A EngertGerman Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany.
S MarnitzMedical Faculty, Department of Radiooncology, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with classical Hodgkin's lymphoma (cHL) have a good prognosis even in advanced stages. However, combined chemo- and radiotherapy, as the standard of care, is also associated with treatment-related toxicities such as organ damage, secondary neoplasias, infertility, or fatigue and long-term fatigue. Many patients suffer from this burden although their cHL was cured. Therefore, the efficacy of immune checkpoint inhibitors like anti-PD1/PD-L1 antibodies in the treatment of solid cancers and also in HL offers new options. A remarkable and durable response rate with a favorable toxicity profile was observed in heavily pretreated cHL patients.

methodsPlanning to perform prospective randomized clinical trials in the content of radio-immune treatment in patients with Hodgkin's lymphoma (HL), we transferred the results of preliminary clinical studies and basic research in clinical relevant study concepts.

resultsBased on these promising early phase trial data, the German Hodgkin Study Group (GHSG) will investigate innovative treatment regimens in upcoming phase II trials.

conclusionThe therapeutic efficacy and potential synergies of anti-PD1 antibodies in combination with chemo- or radiotherapy will be investigated in various settings of HL.

Indexed as

Randomized Controlled Trials as TopicAntibodies, MonoclonalCell Cycle CheckpointsChemoradiotherapyForecastingGermanyHodgkin DiseaseHumansMolecular Targeted TherapyProgrammed Cell Death 1 ReceptorRadiation OncologyRadioimmunotherapyTreatment OutcomeAntibodies, MonoclonalPDCD1 protein, humanProgrammed Cell Death 1 ReceptorAbscopal effectImmune modulationOrgans at riskProgrammed cell death protein 1Radio-immune therapy

Identifiers

PMID27704149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.